Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will step down.
Bradley Campbell, who led Amicus Therapeutics until its recent $4.8 billion acquisition by BioMarin, will become Travere’s new CEO on Dec. 1, 2026. Dube will continue to serve as executive advisor through Feb. 15, 2027, to support an orderly transition, Travere said Monday.
Dube is leaving after a nearly eight-year tenue to “focus on his health and family,” according to Travere.
“My own experiences with rare disease have also given me a profound appreciation for health, family and time,” Dube said in a statement. “After considerable reflection, I’ve decided this is the right moment for me to step away from full-time operating roles and devote greater attention to those priorities.”
In a LinkedIn post, Dube reflected on his experience as a two-time survivor of rare cancer, first diagnosed more than 20 years ago.
“Patients and families remind us every day how precious health, family and time are. And yet those of us who devote ourselves to serving and advocating for others can become so committed to the mission that we sometimes sacrifice those very things in our own lives,” he wrote. “I’ve decided it’s time for me to listen more closely to that lesson.”
About a year after becoming CEO, Dube installed the Travere name to disassociate the company then known as Retrophin from its founder, “pharma bro” Martin Shkreli. In 2023, the company won an FDA accelerated approval for its immunoglobulin A nephropathy (IgAN) medicine Filspari.
The drug received its full approval in 2024 and went on to snag the first FDA approval for another rare kidney disease, focal segmental glomerulosclerosis (FSGS), this April.
“We have built a company, leadership team and culture capable of carrying this mission forward well beyond any one person. That gives me tremendous confidence that this is the right time—for Travere and for me,” Dube wrote in the LinkedIn post.
Taking the baton from Dube, Campbell comes with more than 20 years of experience in the rare disease field. He joined Amicus in 2006 and succeeded founder and long-time helmsman John Crowley in 2022.
Travere’s board hired Campbell after a “thoughtful and comprehensive search process focused on the experience and leadership qualities required for the company’s next chapter,” chairman Gary Lyons said in a statement. “Bradley stood out for his unique combination of scientific, commercial and operational expertise, his proven ability to scale innovative rare disease therapies and advance clinical pipelines, and his track record of significant growth and value creation.”
During Campbell’s tenure, Amicus graduated from a single-product company in 2023 after scoring FDA approval for its Pombiliti + Opfolda regimen for Pompe disease.
In his statement, Campbell touted Travere’s commitment to the rare disease community, its culture and progress.
“I see an exciting opportunity to build on that momentum, reach more people living with rare disease and continue creating meaningful value for all stakeholders,” Campbell said.
Campbell is inheriting Travere on a growth trajectory. In the second quarter, U.S. sales of Filspari nearly doubled year over year to $141 million, as its initial FSGS launch progress outperformed analysts’ expectations.
Meanwhile, the IgAN market is getting increasingly competitive. In 2023, Filspari became just the second IgAN drug approved by the FDA. With an FDA target action date of Nov. 30, 2026, Vertex’s povetacicept is now slated to become the seventh.
The San Diego biotech recently expanded its pipeline, paying $112.5 million upfront for an oral BTK inhibitor called civorebrutinib from China’s Everest Medicines for development in immune-mediated kidney diseases.